RNA sequencing of non–small cell lung cancer (NSCLC) patient-derived xenograft (PDX) tissues following chloroquine (CQ) treatment
Functional lysosomes are essential for tumor growth. CQ, a widely used lysosome inhibitor, has been combined with various other therapeutics for testing in cancer patients. However, no studies have reported enhanced antitumor effects from these treatments. To investigate how tumor cells survive CQ-mediated lysosome inhibition, we conducted transcriptome analysis using RNA sequencing (RNA-seq) on  an adenocarcinoma NSCLC patient-derived xenograft (PDX #72-1001) to compare gene expression changes between control (vehicle) and CQ treatment groups.